Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    medac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

    Virtual Booth

    Contact Supplier

    Coral

    Virtual Booth

    Contact Supplier

    ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.

    Virtual Booth

    Contact Supplier

    Menu

    Cirtuvivint

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    1st Patient Dose in Trial of Biosplice's Cirtuvivint for Leukemia
    1st Patient Dose in Trial of Biosplice's Cirtuvivint for Leukemia

    09 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/09/3146697/0/en/Biosplice-Therapeutics-Announces-First-Patient-Dosed-in-NCI-Sponsored-Clinical-Trial-of-Cirtuvivint-in-Acute-Myeloid-Leukemia-and-Myelodysplastic-Syndromes.html

    GLOBENEWSWIRE
    09 Sep 2025
    Share Share
    Biosplice: First Patient Dosed in Phase 2 Trial of Cirtuvivint
    Biosplice: First Patient Dosed in Phase 2 Trial of Cirtuvivint

    01 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/01/3072165/0/en/Biosplice-Announces-First-Patient-Dosed-in-Phase-2-Trial-of-Cirtuvivint-for-Advanced-Soft-Tissue-Sarcomas.html

    GLOBENEWSWIRE
    01 May 2025
    Share Share